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Background: Inner ear evoked potentials are small amplitude (<1 μVpk) signals that
require a low noise signal acquisition protocol for successful extraction; an existing such
technique is Electrocochleography (ECOG). A novel variant of ECOG called
Electrovestibulography (EVestG) is currently investigated by our group, which captures
vestibular responses to a whole body tilt. The objective is to design and implement a
bio-signal amplifier optimized for ECOG and EVestG, which will be superior in noise
performance compared to low noise, general purpose devices available commercially.
Method: A high gain configuration is required (>85 dB) for such small signal recordings;
thus, background power line interference (PLI) can have adverse effects. Active electrode
shielding and driven-right-leg circuitry optimized for EVestG/ECOG recordings were
investigated for PLI suppression. A parallel pre-amplifier design approach was investigated
to realize low voltage, and current noise figures for the bio-signal amplifier.
Results: In comparison to the currently used device, PLI is significantly suppressed by the
designed prototype (by >20 dB in specific test scenarios), and the prototype amplifier




@ 1 kHz (0.45 μVRMS with bandwidth
10 Hz-10 kHz), which is lower than the currently used device generated noise of 7.8 nV=ﬃﬃﬃﬃﬃﬃ
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) radio frequency interference filter
was realized to minimize noise contribution from the pre-amplifier, while maintaining the
required bandwidth in high impedance measurements. Validation of the prototype
device was conducted for actual ECOG recordings on humans that showed an
increase (p < 0.05) of ~5 dB in Signal-to-Noise ratio (SNR), and for EVestG
recordings using a synthetic ear model that showed a ~4% improvement
(p < 0.01) over the currently used amplifier.
Conclusion: This paper presents the design and evaluation of an ultra-low noise
and miniaturized bio-signal amplifier tailored for EVestG and ECOG. The increase in
SNR for the implemented amplifier will reduce variability associated with bio-features
extracted from such recordings; hence sensitivity and specificity measures associated with
disease classification are expected to increase. Furthermore, immunity to PLI has enabled
EVestG and ECOG recordings to be carried out in a non-shielded clinical environment.
Keywords: Active shielding, Bio-signal amplifier, Electrocochleography,
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Development of low noise bio-signal acquisition devices have evolved substantially
since the inception of the amplified electrocardiogram in the late 1940’s [1], due to the
demand for high resolution electrophysiological measurements and increased patients’
safety [2]. One such method that demands a high resolution signal acquisition protocol
is Electrocochleography (ECOG), a specialized technique that captures electrical activ-
ity from the cochlea, where the signal of interest can range from 0.1-2 μV for the extra-
tympanic approach [3]. In this work the averaged electrocochleograph waveform is
referred to as the ‘averaged field potential’ (AFP) that includes the summing potential
(SP), and the whole nerve-action potential (AP) (see Figure 1). Bio-features identified in
the AFP has enabled ECOG to be a useful clinical tool for diagnosis and monitoring of
a balance disorder called Ménière’s Disease [3,4].
Our group is developing a novel technique called Electrovestibulography (EVestG)
[5], a variant of ECOG, to be used as a diagnostic assistive tool for a subset of neuro-
logical disorders such as Depression, Parkinson’s Disease, and Schizophrenia [6,7]. In
comparison to ECOG, EVestG captures electrical activity predominantly from the ves-
tibular labyrinth during movements (which is analogues to the sound stimulus used in
ECOG), while using a similar recoding topology (described in II). Research over the last
decade shows that bio-features extracted from vestibular FP’s has potential to be used
for classifying healthy subjects from patient groups [5]. The vestibular FP is assumed to
be smaller (<1 μVpk) than the cochlea FP as the recorded response is not from stimulat-
ing the whole (or a tonal range of ) auditory system in a synchronous response [3],
rather, from detecting the spontaneous (or driven) response of smaller groups of “syn-
chronously” firing otoacoustic hair cells. EVestG recordings are currently obtained
using a commercially available, bench-top, low noise bio-signal amplifier in a sound at-
tenuated electrically shielded chamber to reduce background interference. However, it
is desired to implement a miniaturized ultra-low noise amplifier to reduce noise contri-
butions from the recorder, and make EVestG a portable technology to be used in a
clinical setting without the shielded chamber. The current apparatus has two major
















Figure 1 Typical ECOG response.
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chamber. Second, the general purpose amplifier is not optimized for ECOG/EVestG re-
cordings, hence limits high signal-to-noise-ratio (SNR) recordings that can be achieved
if unique differences associated with the recording topology were identified and
accounted for (detailed next).
Many groups have implemented low noise, bio-signal amplifiers with particular appli-
cations in neural recordings [8-13] using CMOS processes. Their common motivation
was to develop the bio-signal amplifier to attain: low noise and low power characteris-
tics, consume a small footprint, and to be integrated in multi-electrode systems. How-
ever, the referred to input (RTI) noise figure for these amplifiers [8-13] are >1.94
μVRMS (for varying low pass cut off frequencies in the range 5 kHz to 9 kHz), and with
varying mid-band gain values in the range 40-60 dB. For EVestG recordings we strictly
require an ultra-low noise (<1 μVRMS) bio-signal amplifier with bandwidth 10 Hz-
10 kHz, since amplifier generated noise ultimately dictates the lowest amplitude signal







to account for high input impedance scenario’s (not addressed
in amplifier designs listed above).Background
ECOG/EVestG recordings are obtained by placing a specialized ear electrode proximal
to the tympanic membrane (TM) via the ear canal, and a reference electrode on the
earlobe. The difference between EVestG and ECOG recording topologies is that, the
reference electrode is typically placed on the contralateral earlobe for ECOG [3], and
on the ipsilateral earlobe for EVestG [5]. Noise associated with ECOG recordings are
reduced by averaging FP’s resulting from auditory clicks, where all noise sources uncor-
related with the sound stimulus would diminish, leaving behind the AFP. EVestG in
contrast, records spontaneous and driven vestibular FP’s, both at rest and when evoked
by the vestibular stimulus through a whole body tilt [5]. These spontaneous FP’s occur
at unknown times and time intervals, hence are extracted by a proprietary software al-
gorithm called the Neural Event Extraction Routine (NEER) [14]. The algorithm’s FP
detection accuracy is found to be largely dependent on three main types of interference
present in the recording [15]: 1) biological signal interference within the bandwidth
40-500 Hz that is comprised predominantly of muscle activity [5]), 2) power line inter-
ference (PLI) (predominantly odd harmonics), and 3) system generated noise (where
effects are significant for frequencies above 500 Hz).
In common electrophysiological measurement techniques such as, electrocardiog-
raphy (ECG), electromyography (EMG), and electroencephalography (EEG), typically
identical electrodes are used for the differential electrode pair. In contrast the differen-
tial electrodes used for ECOG and EVestG are physically different, since the active elec-
trode is a specialized one inserted in the ear canal, which is different from the
reference electrode placed on the ear lobe. This mismatch of electrodes results in mis-
matched input impedances and cause common mode signals to be converted to differ-
ential mode, thus reducing CMRR of the system and increasing susceptibility to PLI
[16,17]. As a preliminary step towards designing an appropriate amplifier configuration,
the existing impedance mismatch was verified experimentally by immersing identical
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mismatched impedance values verses frequency for the two types of electrodes used;
the solid green curve represents the reference electrode (ear lobe electrode), and the
dashed line represents the ear electrode (each measurement was repeated 4 times and
averaged; the worst case coefficient of variance (CV) for measurements was 5.2%), that
would lead to large common mode signals. To attenuate common mode signals, suc-
cessful digital filtering (post processing) approaches have been reported for ECG appli-
cations [18,19]. However, post processing alone does not suffice for large gain (>85 dB)
applications, since saturation of the recording device can often occur due to PLI.
Therefore, a driven right leg circuit (RLD) popularly used in electrophysiological mea-
surements [1,16,18,20] was investigated in the prototype design (in section III) to
minimize PLI from the source.
Noise added by the recording apparatus (system noise) has a substantial effect on low
amplitude recordings. Figure 3 illustrates a power spectrum of a 5 minute long ECOG
recording, where the horizontal dashed line is indicative of system noise (a collection
of noise generated by the amplifier, electrodes, and the electrode/skin interface
[19,21,22]), and the low frequency (<1 kHz) component (solid line) corresponds to bio-





when tested at the connector box located approximately 1 m away from
the device, which is also required to be minimized. Hence, detailed in this paper is the
design, implementation, and validation of an ultra-low voltage and current noise ampli-
fier tailored for ECOG and EVestG based on identified differences associated with
recordings using commercially available components.Materials and methods
The proposed amplifier design consists of three major components to overcome the is-
































Figure 2 Impedance plots for the 2 electrode types used, and typical skin impedance measured
from a test subject connected for EVestG recordings.
Figure 3 Power spectrum density of a 5 min long ECOG recording. The power axis is referenced to
1 Vrms.
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http://www.biomedical-engineering-online.com/content/13/1/61. Power-line Interference rejection using a driven right leg (RLD) topology
2. Active Shielding
3. Ultra-low noise Preamplifier design
In subsequent sections the requirements for these features are detailed, followed by
validation testing.
A)The patient-amplifier interface model with RLDFigFigures 4 and 5 illustrates circuit models [16,20,23-25], when a person is connected
with electrodes for an ECOG recording. Figure 5 shows inputs to the amplifier with
intrinsic impedances from electrodes/leads and skin, and power line displacement
currents and their pathways. For our scenario CSUP (Figure 5) is negligible since theure 4 Right leg driver circuit. The cross section of the ear was adapted from [25] with permission.
Fig
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to the shield conductor around the differential electrodes; however, PLI coupling
from CC1 and CC2 to the inner conductors are reduced due to this shield. By
employing active driven shields, the parasitic capacitances CE1 and CE2 will be
minimized (detailed in part III B), thus displacement currents idC1, idC2, and idSUP
are negligible. However, it must be noted that neglecting these displacement
currents do not affect the common mode voltage (VC) derived in subsequent
equations, since it is based on the total displacement current id2 as derived in (3).
Since displacement currents flowing in and out of the body must equate:id ¼ id1 þ id2 ð1Þ
where id2 is flowing from the body to the common (COMM) electrode. The current div-
ision between CISO and Cb is used to express id2 as follows:
id2 ¼ CISOCISO þ Cb id ð2Þ
Then the common mode voltage VC isVC ¼ id2⋅ZRLD ð3Þ
where ZRLD is the impedance between the VC node and circuit ground. If the COMM
electrode was connected to circuit ground, then:
ZRLD ¼ Z3 þ RE3: ð4aÞ
Figure 4 shows the COMM electrode driven by the RLD circuit (shown separatelyfrom Figure 5 for clarity). The RLD circuit consists of an inverting amplifier with
gain G ¼ RfRk
 
with a corner frequency set at 1.5 kHz. The RLD circuit is driven by
the signal common to both the differential electrodes (known as the common mode
voltage). By driving the COMM electrode with an inverted VC with gain (G + 1),
the effective impedance ZRLD simplifies toure 5 Circuit model for power line interference for ECOG recordings.
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From (2), (4b), and (3), VC can then be expressed, for the Sa position in Figure 4, as:FigVC ¼ id2⋅ Z3 þ RE3Gþ 1
 
¼ CISO





For the case when the Ro resistor is outside the feedback loop (Sb position, seeFigure 4), the impedance of Ro will also be added to the effective impedance ZRLD;
henceVC ¼ CISOCISO þ Cb id⋅




and from (2) and (3), if the 3rd electrode is grounded
VC ¼ CISOCISO þ Cb id⋅ Z3 þ RE3ð Þ: ð5cÞ
From the three Equations (5a, b and c), it is seen that the lowest VC value isattained from (5a) since the term R0 is not incorporated in the Equation.
B Active Shielding
Shielded electrode leads are used to reduce PLI coupling [23,25,26]. Typically shield
connectors are tied to ground, but results in parasitic capacitances (CE1 and CE2 of
Figure 5) between the center conductor and shield (labeled as “Shield” in Figure 6).
In high resolution, large bandwidth bio-signal recordings, this parasitic capacitance
degrades the recorded signal due to two phenomena. First, with increased frequency
the input impedance seen from the electrode (Zin) is reduced. Hence the signal
amplitude at the amplifier input Vin attenuates due to voltage division shown in
Equation (6), where Zin(ω) = RE2 + 1/jωCE2, and ZE2 is the impedance between the
electrode surface contact and circuit ground.
V in ωð Þ ¼ V source⋅ Zin ωð ÞZin ωð Þ þ ZE2 ð6Þ
Secondly, the parasitic capacitances between the differential pair (CE1 and CE2) maydiffer (Figure 5), resulting in an impedance imbalance at the inputs and degrade
CMRR at high frequencies.ure 6 Electrical model of electrode Shield.
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drives the shield conductor. Driving the shield (using high speed op-amps with
Gain-bandwidth-product of 18 MHz) with this signal maintains a near-zero
potential across the lead conductor and shield. Therefore any current conducted by
these capacitances (CE1, CE2) will be reduced; thereby contributing to high input
impedance.
C Ultra-Low Noise Preamplifier Design











. The noise model of a generic amplifier can be
represented as shown in Figure 7 [27] (note that the noise sources shown represent
voltage and current noise densities). Then the total RTI noise power spectrum
density (PSD) Φtotal can be depicted as follows:
Φtotal fð Þ ¼ E2n fð Þ þ E2Zin fð Þ þ Z2in fð Þ
		 		⋅I2n fð Þ ð7Þ
Here, the thermal noise of Zin is E
2
Zin fð Þ ¼ 4kBT⋅Re Zin fð Þ½  [28] (kB is theFigBoltzmann constant, and T is the temperature in Kelvin), and Z2in fð Þ
		 		⋅I2n fð Þ is the
voltage noise due to the current source in conjunction with the input impedance
Zin. The noise component E
2
Zin fð Þ is contact dependent; the quantities E2n fð Þ and I2n
fð Þ are voltage noise and current noise sources of the pre-amplifier model respectively.
The RTI noise (RMS) value can then be calculated as follows:RTI NoiseRMS ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
∫f2f1Φtotal fð Þ df
q
ð8Þ
In (8), f1 and f2 are high pass and low pass cut off frequencies of the analyzed signalrespectively.
Currently available low noise operation amplifiers (OP amps) with bipolar











[27], and precision FET input






, but with larger




. A low current noise amplifier design is necessary in
such bio-signal recordings since high input impedances (Zin) are common (see skin
impedance plot in Figure 2). Therefore to achieve both low E2n fð Þ and I2n fð Þ,ure 7 Amplifier noise model.
Fig
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since the noise introduced by each amplifier is uncorrelated (N is the
number of amplifiers in parallel).
However, there are consequences to parallelization that affect the performance of
the overall amplifier. Three of them are: 1) the current noise will increase by In⋅ﬃﬃﬃﬃ
N
p
; 2) the input resistance reduces by RinN , and 3) input capacitance increases by
Cin ⋅N. Maintaining input impedance as large as possible is necessary to minimize
signal distortion due to loading effects [30]. In addition, the input capacitance
increase reduces the overall amplifier bandwidth, where the low pass cut off
frequency will be dictated by fLP = 1/[2π(RLoad ⋅Cin)] (RLoad is the load resistance).
The designed preamplifier module (see Figure 8) is comprised of the following; a high
impedance ultra-low current noise buffer stage G ¼ 0 dB and En ¼ 4 ﬃﬃﬃ2p nV= ﬃﬃﬃﬃﬃﬃHzp ,
a low noise RFI filter stage En ¼ 1 nV= ﬃﬃﬃﬃﬃﬃHzp , followed by a low voltage noise gain
stage G ¼ 32 dB and En ¼ 1 nV= ﬃﬃﬃﬃﬃﬃHzp  (detailed in the next subsection). It is advan-
tageous to implement the input stage with gain >0 dB for improved noise perform-
ance; however, tolerance levels of resistor components are required to be in the
0.0001% regime to maintain >100 dB of CMRR [31]. As a compromise between noise
performance and CMRR, a unity gain parallel pre amplifier approach was used, where
the grayed out buffers are parallelized as shown in Figure 8. The simulated amplifier
characteristics, with increased N, are summarized in Table 1. To investigate the con-
tribution of current noise, Zin = 1 MΩ is used to mimic poor skin contact. The ther-




p ¼ 129 nV= ﬃﬃﬃﬃﬃﬃHzp : The total noise Φtotal(1 kHz) is calculated
from (7).
For N = 1 to 3, Φtotal(1 MΩ) is constant since the contribution of current noise is
insignificant due to small In. Note that Φtotal(no load) for the case Zin = 0 Ω does




because the entire pre-amplifier is not parallelized;
only the buffered high input impedance stage is parallelized (Figure 8). In our de-
sign, for a load of 1 MΩ, the amplifier bandwidth decreases to 8.8 kHz for N = 2,ure 8 Parallel amplifier block diagram.
Table 1 Noise Performance with Increased Parallelization
Φtotal(1 kHz) 0 Ω load Φtotal(1 kHz) 1 MΩ load ln Cin Rin Bandwidth for
1 MΩ load












9 pF ~10 TΩ 17.7 kHz












18 pF ~5 TΩ 8.8 kHz












27 pF ~3 TΩ 5.9 kHz
Fig
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The implemented pre-amplifier had N = 2 with characteristics highlighted (bolded).
In bio-signal amplifier design applications RFI filtering is commonly employed at
the input stage to attenuate HF content ahead of the instrumentation amplifier [32]
(see Figure 9). RFI suppression minimizes DC output offset errors that can occur
due to strong RF signal rectification in the instrumentation amplifier. The employed
RC network is realized such that the common mode signal cut off frequency is
higher than the differential mode cut off frequency as shown in (9a,b) [32], which
minimizes CMRR degradation due to small variations in mismatched input imped-
ances (RA and RB).FcutCM ¼ 12πRCc ð9aÞ
FcutDiff ¼ 12πR 2CD þ Ccð Þ ð9bÞ
where R is the skin impedance (RA or RB) + RF
However, large mismatched differential inputs seen in ECOG/EVestG recordings
(Figure 2) would lead to mismatched corner frequencies for the RFI filter if the
traditional method is used; thus resulting in degraded CMRR and reduced signal
bandwidth.
In commonly used bio-signal measurements, such as ECG/EEG/EMG, bandwidth
reduction from the RFI filter due to large input impedances is negligible since the
required signal bandwidth is <1 kHz. In contrast, the signal bandwidth of EVestG
recordings spans up to 10 kHz, hence will be affected by bandwidth reduction.
Secondly, with the traditional method (see Figure 9), CD and CC capacitors need toure 9 Traditional RFI filter network.
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fore large resistors (>5 kΩ) are required to realize the desired corner frequencies




from a 5 kΩ resistor is clearly
unacceptable for this work, since the stringent low noise requirements wouldn’t be
achievable if the traditional RFI filter network was employed. With the aid of the
proposed RFI filter topology (see Figure 8) the following were achieved:
 Large mismatched input impedances will have no effect on the RFI corner
frequencies.





contribution, since there is no strict restriction on the values
CD and CC to satisfy the required RC value. The capacitances CD and CC were
therefore set at 1 nF and 5.6 nF respectively to obtain a ~200 kHz cut off
frequency, while accounting for ~50 Ω output impedance on each side of the
paralleled high impedance buffers.
D Overall Amplifier Design
The overall amplifier block diagram, with the customized features described above,
is shown in Figure 10. To maximize low noise performance, the pre-amplifier stage
requires a large gain; however large DC offsets (~100 mV) often occur between the
differential pair in bio-signal measurements due to the ‘half cell potential’ [30,33]
that develops across the electrode and electrolyte interface. Hence a compromise
between noise performance and stability must be met. After extensive test
recordings, the pre-amplifier gain stage was set at 32 dB that maintained stability
and low noise performance during recordings. After the pre-amplification, a 1st
order Butterworth high pass (HP) filter is employed to decouple frequency
content below 1.6 Hz.
EVestG requires minimal phase distortion from the recording device, within the
frequency band up to 9 kHz, since the NEER algorithm’s FP detection is based on
phase changes across multiple scales obtained by a wavelet decomposition [5].
Hence an 11 kHz 4th order Bessel Filter was employed as the primary low pass (LP)
filter, which has maximally flat group delay characteristics.
Even though efforts were made to reduce power line harmonics with active
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with a 20 dB depth and quality factor of 20 was employed. The output stage
consists of a HP filter that decouples DC offsets introduces by active components
in the circuit, and a variable gain stage (0 dB-20 dB). Table 2 summarizes
parameters of the designed and implemented circuit.
E Experimental Setup
A CED 1401 analog-to-digital converter was used for all data acquisitions with
sampling rate of 44 kHz. The prototype amplifier circuit ground was tied to the
CED 1401 ground terminal, which was powered by a medical grade isolation
transformer (POA MG240-1500-2-2010), thereby maintaining patient isolation
from mains power. A CED-1902 amplifier with 1 Hz-10 kHz Bandwidth currently
used for EVestG, was used to evaluate performance of the prototype amplifier.
Power-line interference analysis was performed on the RTI signal, and referenced to 1
VRMS for computing the power spectrum in the dB scale. Noise figure comparisons
are shown in two units: μVRMS: which is the RMS value of the recorded signal within




: which is the power spectral
density value at 1 kHz.
F Electrocochleography (ECOG) Recording Setup
A conventional ECOG electrode setup was used [32], where a disposable TM-
ECochGtrode (Bio-Logic) ear electrode is placed proximal to the TM, a reference
electrode (ELS254S) placed on the contralateral earlobe, and the common electrode
(ELS258S) placed on the forehead (Figure 5). A click stimulus was applied to the
ipsilateral ear at 5.4 Hz with alternating polarity. The pulse width was set at 100 μs;
with click intensity set to a loud but not uncomfortable level for the subject as it is
common practice for ECOG recordings. Test subjects were volunteers (age 29 ±4, 3
males) with no record of hearing loss. Five minute recordings were taken while the
subject was seated in a chair in an anechoic chamber. Ten millisecond windows of
data from the start of each click (positive and negative separately) are extracted and
averaged to reveal the AFP plot. Then, the action potential (AP) magnitude is
measured (Figure 1).ble 2 Overall circuit parameters
Parameter Measured








Input Impedance *5 TΩ | 18 pF
THD (@1 kHz, 0.2 V) 0.0012%
CMRR (@100Hz) 115 dB
Mid-band gain 89 dB
Bandwidth 5 Hz-10 kHz
ax input voltage swing ±180 mV
Power supply ±9 V Batteries
Total current 64.2 mA
rinted circuit board size 9.9 cm X 5.4 cm
Patient isolation *2 pF (from mains ground)
alues obtained from datasheets and simulations.
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Vestibular FP’s occur at unknown times and time intervals; hence qualitative
analysis of the accuracy of captured FP’s from a human recording cannot be
obtained for EVestG. One possible method of analysis is to obtain an additional
trans-tympanic recording alongside the regular EVestG recording and compare the
accuracy of captured FP’s. However, this would be an invasive approach. Instead, an
artificial ear (middle ear and inner ear) [15] constructed to simulate electrical activity
was used to compare the performance of the prototype amplifier for EVestG recordings.
With the artificial ear, various sources of noise present in actual recordings can be
applied at realistic proportions and be picked up by electrodes placed on the simulator.
Cochlear AFP’s recorded in our recent work, and AFP shapes shown in [4,34] were used
as a guide to generate the synthetic FP used. The FP detection accuracy of NEER was
then evaluated for the prototype amplifier, and compared with that of the OEM
amplifier in identical recording conditions.
Experimental results























comThe prototype amplifier common (COMM) electrode is driven by the RLD circuit
where Rf and Cf values set the LP corner frequency at 1.5 kHz, and G ¼ RfRk ¼ 88
was experimentally chosen since it produced the optimum CMRR from low
frequencies (50 Hz) through to higher order harmonics (650 Hz) that are present in
recordings. For ECOG recordings, the effect of PLI was tested for three cases of
connecting the COMM electrode (see Figure 11a); RLD with switch on ‘Sa’ position,
RLD with switch on ‘Sb’ position, and when the COMM electrode was grounded
(node COMM_C in Figure 4). Recordings for each variant were 60s long, and were
from the same subject obtained during one session with the same connected
electrode leads. The prominent harmonics seen are the first harmonic (50 Hz), 3rd
harmonic (150 Hz), and the 9th harmonic (450 Hz), hence the remaining







(b)Power line interference comparison for RLD Vs Grounded common
Grounded
RLD with series resistor in FB loop
RLD with series resistor







 Overall power line rejection comparison for CED Vs prototype 
in noisy environment, untreated skin contacts
Prototype amplifier
CED amplifier


























 Overall power line rejectioncomparison for CED Vs prototype  













ure 11 Power Line interference comparisons for RLD circuit (a), active shielding (b), and overall
parison of CED Vs prototype amplifier (c) and (d).
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suppressing power-line interference, while both RLD topologies are better compared
to the grounded case (5c). By employing an RLD topology VC is attenuated for (5a)
and (5b) in comparison to (5c), which increases overall CMRR of the system.
B Active Shielding
To evaluate PLI suppression as a result of active shielding, the RLD was bypassed,
and the recordings were taken outside the anechoic chamber to enhance PLI. Five
recordings of each case were obtained for 30 seconds and averaged. Power
harmonics beyond 650 Hz are not visible since they are buried in the noise floor.
We see that power line harmonics are reduced by at least 15 dB at frequencies
(50 Hz, 150 Hz and 450 Hz) when active shielding was employed (Figure 11b).
C Overall Performance of the Proposed Amplifier in Comparison to OEM System
1. Power Line Interference SuppressionA large PLI scenario (that can occur during EVestG recordings) was mimicked
by turning on the mains power driven lights inside the anechoic chamber, and a
test subject was connected with electrodes for the EVestG topology. Sixty
second recordings were taken from each amplifier for the same subject with no
skin preparation to simulate poor contact, hence accounting for large
impedances and impedance mismatches. The power spectrum results are shown
in Figure 11c, where the prototype amplifier demonstrates PLI suppression
of ~20 dB in comparison to the OEM amplifier (labeled CED) spanning up to
950 Hz. When the reference and common electrode sites were thoroughly
exfoliated (Figure 11d), PLI suppression for both amplifiers is improved (due to
reduced input impedance, hence reduced impedance mismatch), yet the
prototype amplifier demonstrates better immunity as can be seen in Figure 11d.
2. Low Noise Performance
Noise performance of the CED amplifier and prototype amplifier were measured
with respect to known input impedances (Figure 12). The prototype amplifier
and CED amplifier were measured to have a “0Ω load” noise floor of 4:8 nV=ﬃﬃﬃﬃﬃﬃ
Hz
p




0:76 μV RMSÞð respectively. The noise
performance by impedances above 200 kΩ was not compared since the CED
amplifier bandwidth is reduced below 1 kHz due to parasitic input capacitances
at the input stage (see section III C).
3. ECOG Comparison
To evaluate SNR of the developed amplifier, ECOG recordings were obtained from a
volunteer using both amplifiers in one session, while the sound stimulus was
maintained at the same level. Two noise statistics were identified and compared: PLI
(see Figure 13a), and the voltage noise spectrum (RTI) of the two recordings
(Figure 13b). Towards low frequencies the curves overlap, which shows that the
biological activity is similar in energy (as expected) for both recordings; however,









at high frequencies, which
is indicative of the reduction in noise for the prototype amplifier due to the lower
system noise. SNR calculations (where signal is the AP amplitude of the cochlear
AFP) show that the prototype amplifier recordings were ~5 dB larger (p < 0.05) in











































Figure 12 Prototype and existing OEM amplifier noise performance for varying input impedances,
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The prototype amplifier and CED amplifier were evaluated in the artificial
gelatin setup [15], where the vestibular FP was buried in biological signal activity
(EMG, ECG and EEG) at SNR values−6 to−30 dB in decrements of 6 dB. The
biological signal energy was maintained at 5 μVRMS that approximates
background bio-signal activity captured in actual EVestG recordings. The
performance of each amplifier is summarized in Figure 14, which illustrates the
FP detection accuracy Vs SNR.
The prototype amplifier showed a mean increase in FP detection of 2.7 ± 1.1%


























(a) Power line interference comparison for both amplifiers
CED amplifier with mod electrodes
Prototype amplifier with mod electrodes
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(c) SNR comparison for both amplifiers
Prototype amplifierCED amplifier
ure 13 Comparison of PLI (a), power spectrum (b), and SNR for ECOG recordings (c) with the
amplifiers.
Figure
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http://www.biomedical-engineering-online.com/content/13/1/6background biological activity would be ~0.6 μVrms in amplitude; in comparison,
the prototype amplifier generated noise is 0.45 μVRMS and the CED amplifier
generated noise is 0.76 μVRMS, which is comparable to the FP amplitude.
Therefore the overall increase in FP detection in the prototype can be attributed
to the lower noise performance, and PLI suppression in comparison to the CED
amplifier.Discussion
This work details the design and validation of an ultra-low noise bio-signal amplifier
tailored for ECOG and EVestG. Recordings obtained from volunteers show that the
RLD circuitry with active ground, and active shielding, effectively attenuates PLI in high
bandwidth bio-signal measurements. PLI was shown to be suppressed more effectively
in both shielded and non-shielded environments for the prototype amplifier compared
to the OEM amplifier, which would enable recordings to be carried out in a non-
shielded clinical setting; an essential component to making EVestG a portable technol-
ogy. The RLD circuitry effectively reduces the COMM electrode impedance to circuit
ground; yet the high level of isolation (~2 pF) between circuit ground and Earth ground
limits the mains current flow through the leads (to <0.3 μA in the event that the live
voltage 240 V, 50 Hz appears), and effectively protects the subject.




is rather trivial given
that on chip instrumentation amplifiers are available commercially; however, due to the
large input impedances that can occur in EVestG/ECOG recordings, ultra-low current
noise characteristics are also required. In an attempt to design the amplifier with volt-








range, a unique parallel
pre-amplifier approach was investigated and validated. The traditional method of using
RFI filtering cannot be employed in such low-noise applications due to the large series
resistances required. The drawback of the implemented RFI filter topology is that, the
buffered input stage is susceptible to RFI that could lead to DC offset errors from the
differential pair. However repercussions due to this phenomenon were not seen























14 Prototype and OEM amplifier FP detection Vs SNR.
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http://www.biomedical-engineering-online.com/content/13/1/6In early stages of the design, the preamplifier was configured to have a large (40 dB) gain
to maximize noise performance. The amplifier functioned as expected for EMG, ECG, and
EOG (electrooculogram) recordings, however displayed instability during ECOG and
EVestG recordings. This issue was identified to be caused by mismatched electrodes that
lead to mismatched DC potentials (>180 mV) appearing on each electrode (a result of the
electrodes’ half cell potential [30,33]), causing amplifier saturation. As a result, the preampli-
fier gain was reduced to 32 dB to avoid instability at the cost of a reduction in noise per-








(in simulation). These mismatched DC
potentials between leads indicate that separately driving each lead wire shield would be
more effective in reducing parasitic capacitances CE1 and CE2. Therefore individual active
shields were employed.
μV amplitude ECOG electrical activity obtained from the prototype amplifier show signifi-
cantly higher (p < 0.05) SNR as a result of improved noise performance and improved PLI
suppression; furthermore, FP detection accuracy of the NEER algorithm was also shown to
increase (p < 0.01) for prototype amplifier recordings in identical test scenarios compared to







). The increased FP detection accuracy has significant implications for EVestG; it will
incur a reduction in variability associated with bio-features extracted, which is expected to
result in increased sensitivity and specificity measures used for disease classification.
Table 3 compares key features of state-of-the-art (CMOS) low noise bio-signal amplifiers,
the CED amplifier, and the prototype amplifier. CMOS devices listed, have noise perform-




(> 2-fold worse than the CED amplifier noise performance) which is
inadequate for EVestG, since FP detection accuracy will be further degraded rendering the
methodology ineffective for disease classification. However, for the increase in noise per-
formance of ~5-fold, compared to CMOS devices, the prototype amplifier sacrifices power
consumption and footprint requirements by factors ~104 and ~5x104 respectively. These
substantially large power and footprint requirements however are tractable, since only two
such channels are required for a complete EVestG system; in comparison, CMOS devices
listed are for multi array (hundreds of channels) applications, which require low power and
footprint characteristics per channel to accommodate the entire array. As a result of the
high power and footprint requirements, implementation of an ultra-low noise, multi-
channel recording device with the prototype amplifier is currently not feasible. However,
the prototype amplifier has other applications in low noise recordings such as high reso-
lution ECG [35]. An example would be ventricular tachycardia, a life threatening condition,
described to have low amplitude and high frequency content at the end of the QRS complex
and the ST segment [36]. Accurately extracting such features require a low noise, high
bandwidth amplifier, such as the prototype device presented in this manuscript. Once the
prototype amplifier is validated on a large (n > 20) patient group population, a miniaturized
single chip design will be investigated in collaboration with Texas Instruments that will re-
duce power and footprint requirements.
Outcomes of this work and previous work [15] suggest that amplifier generated noise
is only one aspect that contributes to degrading the quality of the recording. Noise due
to electrodes and biological interference also need to be minimized to maximally utilize
low noise characteristics of the designed prototype amplifier, which will be investigated
to improve the quality of EVestG recordings.
Table 3 Performance comparisons against other systems
Parameters [8] [9] [10] [11] [12] [13] CED ampifier This work
Supply voltage/Current ±2.5 V/16 μA ±2.8 V/2.7 μA 1.8 V/4.7 μA 3.3 V/8 μA 1.8 V/4.4 μA 1.5 V ±15 V/ - ±9 V/64.2 mA
Gain 39.5 dB 40.8 dB 49.5 dB 39.6 dB 39.4 dB 10-62 dB 88.4 dB (configured) 89 dB
Bandwidth 7.2 kHz 45 Hz-5.3 kHz 9.1 kHz 8.2 kHz 7.2 kHz 10 kHz 10.1 kHz 11 kHz
































CMRR ≥83 dB ≥66 dB ≥52.7 dB ≥76 dB 70.1 dB >90.7 dB 117.6 dB (@100 Hz) 115 dB (@100 Hz)
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http://www.biomedical-engineering-online.com/content/13/1/6Conclusion
ECOG and EVestG are electrophysiological measurement techniques that record activ-
ity in the μV range, where susceptibility to various sources of noise severely degrade
SNR. In this paper, an ultra-low noise, and miniaturized bio-signal amplifier tailored for
vestibular and cochlear evoked potentials was designed and evaluated. Based on human
recordings and test-bench evaluations conducted, the prototype amplifier demonstrated
to surpass performance of the current OEM device, and state-of-the-art devices, in
terms of PLI suppression and noise performance for ECOG and EVestG recordings.
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